ApoE rs4420638, transforming growth factor β receptor 1 (TGFBR1) rs334353, CF1 rs4698775, cholesteryl ester transfer protein (CETP) rs3764261 and VEGFA rs943080 and the response to ranibizumab treatment in AMD patients rs744166 were studied by Yamashiro and colleagues, but no correlation between the treatment and patient response was found in AMD patients [141]. This evidence concerns the gene TGFBR1 and age-related macular degeneration.